Comprehensive Intensive Stroke Rehabilitation
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Apr 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special rehabilitation program for adults who have had a stroke. The goal is to see how effective this Comprehensive Intensive Rehabilitation Program is compared to two other rehabilitation approaches that focus on different types of physical therapy techniques. Participants will be divided into groups to receive different types of therapy, while another group will receive standard care. This study aims to help improve recovery for stroke patients by finding out which methods work best.
To join the trial, participants need to be adults who have experienced their first ischemic stroke and have some ability to move after the stroke, meaning they have slight to moderate disability. They should also be able to participate in about four hours of rehabilitation each day. Additionally, participants must be able to communicate in Czech. Throughout the trial, participants can expect to engage in intensive rehabilitation tailored to their needs, with the hope of improving their physical abilities and overall quality of life after a stroke. It’s important to note that individuals with severe medical issues or cognitive challenges may not be eligible for the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults
- • after first ischemic stroke
- • early sub-acute phase
- • slight to moderately severe disability \[2 - 4 on the Modified Rankin Scale\]
- • 0 - 2 on the Pre-Stroke Modified Rankin Score
- • potential to accept 4 hours of comprehensive rehabilitation per day and to profit from physiotherapy
- • minimal or moderate motor deficit of upper or lower extremities (on NIHSS Item 5 or 6 scores 1-3 points)
- • able to perform activities of daily living prior to stroke event (0 - 2 on the Pre-Stroke Modified Rankin Score)
- • Czech is participants' native language or its knowledge is at the level of the mother tongue
- Exclusion Criteria:
- • low level of consciousness (vegetative state and/or minimally conscious state); severe cognitive decline that would interfere with administration of the tests, premorbid illiteracy, severe visual and/or auditory deficit that would prevent proper completion of the tests
- • behavioural disorders and/or lack of cooperation with therapist
- • severe medical problems with a poor prognosis, (e.g., severe frailty, advanced and incurable cancer, fracture, cardiovascular disorders as chronic heart failure NYHA III, IV, symptomatic coronary artery disease Angina Severity Class III, IV, respiratory insufficiency as chronic obstructive pulmonary disease GOLD IV, and other severe disease)
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Patients applied
Trial Officials
Kamila Řasová, Dr.
Principal Investigator
Third Faculty of Medicine Charles University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials